News

May 11, 2022 TORONTO, Canada and RIONEGRO, Colombia (May 11, 2022) – PharmaCielo Ltd. (“PharmaCielo” or the“Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), announces today that, further to its

May 6, 2022 Poland is one of the largest cannabis markets in Europe by patient population, with more than 28,000 prescriptions issued to approximately 10,000 patients in the first nine months of 20211. The Company expects to begin shipping to Poland during the first half

April 4, 2022 Builds on the passing of Regulation 227 in February, which implemented legal provisions to enable dried flower export and access to additional opportunities for CBD-based products. PharmaCielo expects to begin exporting dried flower in the second quarter of 2022, with volumes growing

February 20, 2022 PharmaCielo expects to begin exporting dried flower in the first half of 2022, with volumes growing through the remainder of the year. The Company's upstream and downstream scale and quality uniquely position it to be a formidable competitor with psychoactive flower currently

February  14, 2022 The Company will start supplying the German market with three THC-dominant products, with commercial shipments expected to begin in late 2022. This is PharmaCielo’s first sales agreement related to THC products. Represents a significant milestone related to management’s re-focusing of PharmaCielo’s product

February  4, 2022 • PharmaCielo is actively working with, and has recently shipped product to, established companies in Argentina, Brazil, Colombia and Paraguay. • The Company’s sales and technical teams are providing support to these customers as they conduct testing and advance product registrations using

January 3, 2022 All amounts expressed in Canadian dollars unless otherwise noted TORONTO, Canada and RIONEGRO, Colombia (December 31, 2021) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia

December 22, 2021 All amounts expressed in Canadian dollars unless otherwise noted TORONTO, Canada and RIONEGRO, Colombia (December 22, 2021) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia

November 29, 2021 Received confirmation of Colombian GMP Certification for Phytotherapeutics manufactured with proprietary PharmaCielo extracts and cultivars. Currently working toward EU-GMP certification, expected to be achieved in the first half of 2022. Executing on opportunities to streamline the business – In the three months

September 14, 2021 PharmaCielo Receives Confirmation of Colombian Phytotherapeutics GMP Certification GMP[i] certification has been confirmed by INVIMA. The certification covers Phytotherapeutics manufactured with PharmaCielo´s extracts and proprietary cultivars. PharmaCielo’s Processing and Extraction Centre – the largest in Colombia and one of the largest globally – has